Kurs
-4,53%
Likviditet
30,3 MSEK
Kalender
| Tid* | ||
| 2025-02-06 | 08:30 | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-30 | - | Split EXPRS2 40:1 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-07 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2024-06-05 | - | Årsstämma |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-23 | - | Extra Bolagsstämma 2023 |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-31 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-23 | - | Extra Bolagsstämma 2020 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-07 | - | Bokslutskommuniké 2017 |
| 2017-11-30 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-01 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2017-05-31 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-19 | - | Extra Bolagsstämma 2017 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-08 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, August 25, 2021 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in August. Pareto upheld its `buy' rating with a target price of SEK 68 per share, while Analysguiden has set a new fair value of SEK 55 per share. Both of these reports were published before the August 23, 2021 announcement that the Danish Ministry of Health will fund the ABNCoV2 COVID-19 vaccine program with up to DKK 800 million.
Both research reports are available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website. The next updates from Pareto Securities and Analysguiden are expected following major news.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com